DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the RUBICON RESEARCH LIMITED (RUBICON) share price today?

RUBICON RESEARCH LIMITED (RUBICON) is trading at ₹1,439.6 on the NSE, up 1.45% on the day. Source: DocStoX.

What is the PE ratio of RUBICON RESEARCH LIMITED?

RUBICON RESEARCH LIMITED has a price-to-earnings (PE) ratio of 96.3 in the Healthcare sector.

What is the market capitalisation of RUBICON RESEARCH LIMITED?

RUBICON RESEARCH LIMITED has a market capitalisation of approximately ₹23,699 crore.

RUBICON RESEARCH LIMITED

RUBICON·NSE·Healthcare

₹1,439.60▲ +20.60 (+1.45%)

Healthcare · Pharmaceuticals

Revenue compounding 65% a year

Day₹1390.30

₹1449.00

52W₹571

₹152791%

Open

₹1415.20

High

₹1449.00

Low

₹1390.30

Prev Close

₹1419.00

Volume

2.14L

VWAP

₹1420.97

Snapshot

Key fundamentals

Market Cap

₹23,699 Cr

P/E Ratio

96.29Expensive

P/B Ratio

18.04

EPS

₹14.95

Book Value

₹78.10

ROE

27.00%Strong

ROCE

28.00%Efficient

Dividend Yield

0.11%

Debt / Equity

0.24Low

Face Value

₹1.00

52W High

₹1527.00

52W Low

₹570.75

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹152

▼ 89.5%downside

Trading at ₹1,440 — 89% above our estimate

BearFair valueBull

₹129₹152₹175

/100

Business quality — Solid

Growth 100Profitability 84Efficiency 50Valuation 44

Plain English

Our view

Revenue compounding 65% a year
Low debt relative to equity
Expensive — trades at 96× earnings

Strengths

Low debt relative to equity
Strong returns on equity (27%)
Capital is working hard (ROCE 28%)
Revenue compounding 65% over 3 years

Risks

Expensive — trades at 96× earnings
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

27% ROE fading to 12% over ~10 yrs, on ₹78 book

₹149

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹162

Analyst target

No analyst coverage

—

Blended fair value₹152

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Strong returns on equity (27%)
Capital is working hard (ROCE 28%)
Revenue compounding 65% over 3 years
Promoters hold a controlling stake

Bear case

Expensive — trades at 96× earnings
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

96.3Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

27.0%Strong

Above 15% is considered healthy for Indian equities

ROCE

28.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.24Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹23,699 Cr

P/B

18.04

EPS

₹14.95

Div Yield

0.11%

What changed

Recent changes

Foreign investors-0.5% stake last quarter
Domestic institutions+0.6% stake last quarter
Promoters-0.13% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 96.3×

Growth

Strong

+65% rev CAGR

Profitability

Excellent

27.0% ROE

Financial health

Rock solid

D/E 0.24

Momentum

N/A

No technicals

Today

Trading activity

Delivery %48.5%

Turnover₹3043.53L Cr

Trades19,391

VWAP₹1420.97

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+64.5%

+41.0%

10Y

—

Profit

—

+51.5%

10Y

—

EPS

—

-24.4%

10Y

—

Profile

Pros

Company has reduced debt.
Company has delivered good profit growth of 52.0% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 27.5%

Watch-outs

Cons

Stock is trading at 18.3 times its book value
Working capital days have increased from 68.8 days to 104 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Promoters trimmed their stake by 0.13 pts; foreign investors sold 0.45 pts; domestic institutions added 0.57 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

60%

Promoter

Promoters

59.9%-0.13

Public

2.8%+0.11

FII / FPI

7.5%-0.45

DII

10.0%+0.57

Others

19.8%

Total shareholders

33,738+1,824 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter59.86%

FII7.54%

DII10.02%

Public2.82%

Others19.76%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations.[1]